Dosing · Resolve · GLP-3 RT 10mg
Resolve · Triple-Agonist Complex

GLP-3 RT 10mg

A once-weekly triple-agonist targeting GLP-1, GIP, and glucagon receptors — extended supply window.

99,00 € 10 mg vial In stock
Per reference20units
Cadence1× per week
ReceptorsGLP-1 / GIP / Glucagon
Vial10mg / 2 mL
GLP-3 RT 10mg

About

The same triple-agonist as the 5 mg vial — at a higher mass for longer supply or escalated reference.

Research describes GLP-3 RT as activating three metabolic pathways simultaneously. GLP-1 and GIP drive insulin response and satiety; glucagon agonism uniquely elevates basal metabolic rate. The 10 mg vial suits longer cycles and escalation tiers.

Sequence lists GLP-3 RT under the Resolve category — fat loss, metabolism.

Vial content

10 mg lyophilised GLP-3 RT in an glass vial, reconstituted with 2 mL bacteriostatic water at 5 mg/mL.

At reference, 20 units on a U-50 insulin syringe draws approximately 2 mg (baseline). Rotate between abdominal quadrants.

Storage: refrigerated 2–8°C after reconstitution. Do not freeze.

Reported effects

What the literature
describes.

01

Body fat & waist reduction

02

Blood-sugar & insulin balance

03

Energy expenditure & oxidation

04

Lean-mass preservation

05

Appetite & metabolic regulation

Reported timeline

What the literature
reports, by phase.

Week 1–2
01

Week 1–2 — Reduced appetite, steadier blood sugar, lighter digestion. GI adaptation common.

Week 3–6
02

Week 3–6 — Body composition begins to register. Fat oxidation steady. Food aversion normalises.

Week 6–12
03

Week 6–12 — Visceral fat reduction consolidates. Insulin and lipid markers trend.

Long-term
04

Long-term — Metabolic rate holds at reduced body mass. Retention post-pause with adequate protein and load.

Reference dosing

Reference profile.

Baseline

Standard
20units / week
1 mg · 1× per week
  • Injection siteSubcutaneous · abdomen
  • RotationQuadrant cycle, 7+ days
  • TimingAny time of day

Baseline

Standard
10units / week
1 mg · 1× per week
  • Injection siteSubcutaneous · abdomen
  • RotationQuadrant cycle, 7+ days
  • TimingAny time of day

Unit-to-milligram conversion

UnitsVolume (mL)Dose (mg)Reference
5 0.05 0.50 Microdose
10 0.10 1.00 Baseline
20 0.20 2.00 Escalation · tier 1
30 0.30 3.00 Escalation · tier 2
50 0.50 5.00 Upper reference

Recommended cycle

Up to 40 weeks in clinical trials

Cycling supports receptor sensitivity across all three pathways. The off-phase tests whether the system holds gains without continuous exogenous input.

Vial details

ContentGLP-3 RT · lyophilised
Mass10 mg
Reconstitution2 mL BAC water
Concentration5 mg/mL
Supply (baseline)~10 weeks
Storage2–8°C · do not freeze
Mechanism

Three receptors. One molecule.

GLP-3 RT activates GLP-1, GIP, and glucagon receptors simultaneously. GLP-1 drives glucose-dependent insulin release and satiety; GIP supports insulin sensitivity and adipose signalling; glucagon agonism raises basal metabolic rate — the mechanism that distinguishes it from dual-agonist peptides.

The triple signal produces greater calorie burn and fat oxidation than single- or dual-pathway compounds, with lean-mass preservation reported at reference doses.

  • GLP-1Glucose-dependent insulin release, appetite suppression, slowed gastric emptying.
  • GIPInsulin sensitivity, adipose signalling, co-potentiation of GLP-1.
  • GlucagonRaises basal metabolic rate — calorie burn without appetite cost.
  • Half-lifeWeekly cadence enabled by albumin-bound side chain.
Safety signals

Reported side effects
& contraindications.

Reported side effects
  • Mild nausea or constipation during initial weeks
  • Decreased appetite or early satiety
  • Occasional fatigue as body adjusts
  • Vomiting or delayed gastric emptying (rare)
Contraindications
  • Active malignancy — especially medullary thyroid carcinoma, MEN 2
  • Pregnancy or breastfeeding
  • Known peptide or excipient hypersensitivity
  • History of pancreatitis
  • Severe gastroparesis or GI motility disorders
Discontinue and seek medical advice

Severe abdominal pain, persistent vomiting, allergic reaction, visual disturbance, or signs of pancreatitis — discontinue and seek immediate medical evaluation.

Research chemical · Not for human consumption. This reference is educational only. Sequence does not provide medical services or prescribe. Consult a licensed clinician for any health decision.

Watch it done properly.

Reconstitution, site rotation, storage — on video.

Video guide Back to dosing